CollPlant Biotechnologies Ltd. (CLGN) 股票分析

公司概述

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company dedicated to advancing the 3D bioprinting of tissues and organs, alongside offering medical aesthetic solutions across the United States, Canada, Israel, Europe, and international markets. The firm's product portfolio relies on foundational technologies involving recombinant human collagen, positioning the entity within the broader healthcare sector specifically under the biotechnology industry classification. As of the latest reporting period, the company possesses a market capitalization of $5.54M and employs a workforce of 39 individuals. With an annual revenue (TTM) of $2.37M, the firm presents the financial profile of a small-cap entity, where the modest market cap and revenue figures indicate a limited scale of operations typical for early-stage biotechnology firms that are still establishing their commercial footprint and validating their specialized bioprinting technologies in a competitive therapeutic landscape.

财务健康

CollPlant Biotechnologies reported a revenue of $2.37M over the trailing twelve months, while posting a net income of $-11,489,000 and an EBITDA of $-10,571,000. The significant disparity between the positive revenue of $2.37M and the substantial negative net income reveals a cost structure characterized by high operating expenses that far exceed gross profit generation, a common challenge in research-intensive biotechnology development phases. The company generated a free cash flow of $-5,480,875, indicating a continuous burn rate that consumes cash reserves and suggests limited financial flexibility until commercial milestones are achieved or funding rounds are secured. Margins analysis shows a gross margin of 64.8%, which reflects efficient cost of goods sold relative to sales, yet this is offset by an operating margin of -5250.0% and a profit margin of 0.0%, highlighting that general and administrative costs are extremely high relative to the current revenue base. In terms of leverage, the company holds $5.59M in cash against $2.85M in debt, resulting in a debt-to-equity ratio of 46.80, which implies a balance sheet that is currently leveraged but supported by sufficient liquid assets to cover immediate obligations. The current ratio stands at 2.52, signaling a robust position in short-term liquidity where current assets significantly outweigh current liabilities. Finally, the return on equity is -117.6% and the return on assets is -48.7%, metrics that reveal management is currently unable to generate positive returns on the capital invested or utilized by the company due to the prevailing losses.

估值评估

The valuation metrics for CollPlant Biotechnologies show a P/E Ratio (TTM) of N/A and a forward P/E of -0.98, implying that the difference between these figures stems from the company's lack of earnings and negative expected trajectory rather than a traditional multiple expansion. The price-to-book ratio is 0.81, indicating that the market values the company at less than its book value, which suggests investors are pricing in significant risks regarding the realization of the company's intangible assets and future potential. Alternative valuation measures include a price-to-sales ratio of 2.33 and an EV/EBITDA of -0.26, suggesting that the market is willing to pay a premium relative to sales despite the lack of profitability, a practice often seen in companies with high growth potential or unique technological assets. The stock has traded within a 52-week range between a high of $4.98 and a low of $0.34, and without a specific current price provided in the available facts, the relative trading position cannot be quantified as a percentage deviation from these bounds. The beta value of 0.94 indicates that the stock's price volatility is roughly in line with the broader market, meaning it does not exhibit significantly higher or lower risk than the overall market index.

Growth & Income

CollPlant Biotechnologies experienced a revenue growth (YoY) of -63.4%, while earnings growth (YoY) is listed as N/A due to the absence of positive earnings in the prior period for comparison. The contraction in revenue suggests a challenging commercial environment or a decline in sales volume, and without positive earnings growth to offset this, the company's fundamental trajectory faces headwinds. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that any retained earnings are theoretically available for reinvestment, though the current net income loss precludes actual reinvestment of profits. The overall growth and income profile for CollPlant Biotechnologies is defined by negative revenue momentum and a complete lack of current income distribution, reflecting the reality of a small-cap biotechnology firm navigating significant commercial and operational hurdles.